Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly Accelerates Baricitinib Availability in India Amid Covid-19 Surge

05/04/2021 | 06:17am EDT

By Colin Kellaher

Eli Lilly & Co. on Tuesday said it is donating hundreds of thousands of doses of baricitinib to the Indian government, as the nation of more than 1.3 billion people grapples with a massive Covid-19 surge.

The Indianapolis drug maker said India's government approved restricted emergency use of the drug, which the company markets as Olumiant for the treatment of rheumatoid arthritis, as a Covid-19 therapy via donations and licensing agreements.

The company said it is making an initial donation of 400,000 baricitinib tablets immediately available to the Indian government for eligible hospitalized Covid-19 patients, adding that it is working with Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to speed production and distribution of drug during the pandemic.

Eli Lilly said the emergency authorization covers the use of baricitinib in hospitalized Covid-19 patients who need supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.

The U.S. Food and Drug Administration in November authorized the emergency use of baricitinib in combination with Gilead Sciences Inc.'s remdesivir for Covid-19 patients needing supplemental oxygen or on a mechanical ventilator.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

05-04-21 0817ET

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL 1.06% 34382.13 Delayed Quote.9.74%
ELI LILLY AND COMPANY 0.65% 196.21 Delayed Quote.16.21%
GILEAD SCIENCES, INC. -0.55% 68.53 Delayed Quote.18.28%
All news about ELI LILLY AND COMPANY
05/13Samsung BioLogics says decision pending on making Moderna vaccine as report i..
RE
05/13TORRENT PHARMACEUTICALSá : Signs Licensing Agreement with Eli Lilly for COVID-19..
MT
05/13ELI LILLY ANDá : Lilly to Participate in UBS Global Healthcare Virtual Conferenc..
PR
05/13Push for Covid-19 Vaccine Patent Waiver Isn't a Panacea - but It Could Nudge ..
AQ
05/13ELI LILLY AND COMPANY : Ex-dividend day for
FA
05/11ELI LILLY ANDá : MiNA Therapeutics Launch Research Collaboration
MT
05/11ELI LILLY ANDá : Lilly Starts Global Research Collaboration With MiNA Therapeuti..
MT
05/11ELI LILLY ANDá : Lilly and MiNA Therapeutics Announce saRNA Research Collaborati..
PR
05/11Eli Lilly, MiNA Therapeutics Join in Research Collaboration
DJ
05/10ELI LILLY ANDá : UBS Adjusts Eli Lilly's Price Target to $193 From $170, Modelin..
MT
More news
Financials (USD)
Sales 2021 27 320 M - -
Net income 2021 6 776 M - -
Net Debt 2021 11 229 M - -
P/E ratio 2021 26,7x
Yield 2021 1,70%
Capitalization 178 B 178 B -
EV / Sales 2021 6,94x
EV / Sales 2022 6,74x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 216,04 $
Last Close Price 196,21 $
Spread / Highest target 29,5%
Spread / Average Target 10,1%
Spread / Lowest Target -10,8%
EPS Revisions
Managers and Directors
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Senior VP, Chief Information & Digital Officer
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY16.21%177 205
JOHNSON & JOHNSON7.99%447 572
ROCHE HOLDING AG-2.57%286 766
PFIZER, INC.8.72%223 684
ABBVIE INC.8.82%205 942
MERCK & CO., INC.-4.29%199 248